加载中
NASDAQHealthcareBiotechnology
最新数据
US$2.41
−US$0.11 · -4.37%
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
常规交易时段
US$2.41
−US$0.11 · -4.37%
盘中时间采用ET。市场数据可能有所延迟。
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
日内区间
当前US$2.41
52周区间
当前US$2.41
盘中时间采用ET。市场数据可能有所延迟。
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
日内区间
当前US$2.41
52周区间
当前US$2.41
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 6742.5万 USD | — | — | — |
| 毛利 | — | 6742.5万 USD | — | — | — |
| 研究与开发 | 1.07亿 USD | 1.68亿 USD | 2.35亿 USD | 1.73亿 USD | 1.76亿 USD |
| 销售、一般及管理费用 | 3771.7万 USD | 8711.5万 USD | 5939.8万 USD | 5455.3万 USD | 4094.1万 USD |
| 营业费用 | 1.53亿 USD | 2.59亿 USD | 3亿 USD | 2.27亿 USD | 2.17亿 USD |
| 利息收入 | — | — | — | 2262 USD | — |
| 利息支出 | — | — | — | 257.5万 USD | — |
| 折旧和摊销 | 73.9万 USD | 128.9万 USD | 138.9万 USD | 142.6万 USD | 54.4万 USD |
| 营业利润 | −1.53亿 USD | −1.91亿 USD | −3亿 USD | −2.27亿 USD | −2.17亿 USD |
| 净利润 | −1.37亿 USD | −1.66亿 USD | −2.92亿 USD | −2.37亿 USD | −1.59亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$7.67
上涨空间 218.26%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1074.23万0.00%2.3万亿 USD0.03%US$381.17-0.10%
iShares Russell 2000 ETFIWM327.67万0.00%787.4亿 USD0.19%US$276.86-0.38%
Vanguard Extended Market ETFVXF216.52万0.00%954亿 USD0.05%US$232.62-0.39%
Fidelity Enhanced Small Cap ETFFESM152.16万0.02%64.1亿 USD0.28%US$45.125-0.25%
iShares Russell 2000 Value ETFIWN121.67万0.01%137.49亿 USD0.24%US$210.94-0.07%
Vanguard Russell 2000 ETFVTWO108.49万0.01%180亿 USD0.06%US$111.82-0.40%
Vanguard Health Care ETFVHT84.03万0.00%220亿 USD0.09%US$316.5-1.30%
Federated Hermes MDT Small Cap Core ETFFSCC72.43万0.17%4.27亿 USD0.50%US$33.78-0.44%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTFederated Hermes MDT Small Cap Core ETFFSCCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
